Core Insights - The strategic collaboration between Maiwei Biopharma and DeepMind Technology aims to transform biopharmaceutical research from a traditional experimental-driven model to a computational-driven model, addressing long-standing issues of lengthy R&D cycles, high costs, and low efficiency [1][3] Group 1: Company Overview - Maiwei Biopharma is an innovative biopharmaceutical company with a full industry chain layout, committed to turning innovation into reality and meeting unmet clinical needs globally through source innovation [1][2] - DeepMind Technology is a leader in AI for Science, utilizing AI to learn scientific principles and solve key problems in scientific research and industrial development [1][2] Group 2: Collaboration Details - The partnership will leverage both companies' strengths in biopharmaceutical R&D and AI large models to create a biopharmaceutical R&D large model platform, establishing a new paradigm for innovative drug development [1][3] - Two main areas of collaboration include: - Knowledge Engine Construction: Utilizing the Uni-SMART multimodal scientific literature model to build a knowledge engine for biopharmaceutical innovation, enhancing research efficiency and accelerating the R&D process [2] - Innovative Target Exploration: Combining Maiwei's ADC technology with DeepMind's RiDYMO platform to explore challenging drug targets and improve molecular discovery processes [2]

【导读】医药板块，突传利空 大家好，特朗普突然对医药出手了！ 特朗普计划降低美国药品价格，医药股暴跌 5月12日，虽然市场整体大涨，但创新药板块却逆市大跌。 | 代码 | 名称 . | 涨幅%1 | 现价 | | | --- | --- | --- | --- | --- | | 688062 | 迈威生物-U K -10.96 | | 17.80 | | | 688532 | 自济神州-U K -9.04 | | 221.50 | | | e8826e | 淺環制药-U K | -1.81 | 91.73 | | | 688192 | 迪哲医药-U K | -7.36 | 52.23 | | | 300204 | 舒泰神 | -6.36 | 10.31 | | | 688206 | 百利天恒 ાર | -6.08 | 262.99 | | | 002294 | 信立泰 R | -5.75 | 38'22 | | | 002675 | 东诚药业 R | -5.60 | 13.99 | | | 688068 | 热景生物 ાર | -5.39 | 103.50 | | | 688382 | 益方生物-U K | ...

截至5月12日收盘，重组蛋白概念下跌0.94%，位居概念板块跌幅榜前列，板块内，迈威生物、泽璟制 药、阿拉丁等跌幅居前，股价上涨的有16只，涨幅居前的有*ST万方、百普赛斯、*ST苏吴等，分别上 涨2.73%、2.69%、2.58%。 今日涨跌幅居前的概念板块 | 代码 | 简称 | 今日涨跌幅（%） | 今日换手率（%） | 主力资金流量（万元） | | --- | --- | --- | --- | --- | | 688166 | 博瑞医药 | -3.34 | 3.24 | -9247.96 | | 688266 | 泽璟制药 | -7.80 | 2.14 | -5042.00 | | 300723 | 一品红 | -1.36 | 2.96 | -4614.17 | | 002584 | 西陇科学 | 0.56 | 10.62 | -2062.55 | | 688136 | 科兴制药 | -2.77 | 1.52 | -1992.98 | | 688068 | 热景生物 | -5.39 | 4.08 | -1842.96 | | 600223 | 福瑞达 | -1.08 | 1.40 | -1498.6 ...

Core Insights - The strategic partnership between Maiwei Biopharma and Insilico Medicine aims to leverage AI to enhance the development of Antibody-Drug Conjugates (ADCs), marking a new chapter in collaborative innovation within the biopharmaceutical sector [1][2] Company Overview - Maiwei Biopharma possesses strong capabilities in ADC technology platform construction and antibody discovery, having established a complete industry chain from research and development to production [1] - The company has developed a series of structurally uniform and quality-stable ADC innovative drugs, which have been validated in clinical settings [1] AI Integration - Insilico Medicine is a pioneer in AI-driven drug development, with its integrated Pharma.AI platform covering biology, chemistry, clinical medicine, and scientific research [1] - The platform includes engines like PandaOmics and Generative Biologics, which enhance drug target identification and de novo molecular fragment generation, thereby improving research efficiency [1] Strategic Goals - The collaboration aims to combine the strengths of both companies to develop new generation toxin payloads with novel biological mechanisms, innovative structures, and pharmacological activity, thereby enhancing ADC innovation efficiency [1] - The partnership is expected to lead to significant advancements in ADC research and development, providing more effective treatment options for patients globally and setting a new example for collaborative development in the biopharmaceutical industry [2]

A股创新药概念集体回调，迈威生物跌超10%，百济神州、信立泰双双跌超8%，益方生物、舒泰神、热 景生物、百利天恒、诺诚健华等跌幅靠前。 ...

创新药板块盘初下挫，迈威生物跌超10%，益方生物、舒泰神（300204）跌超9%，百济神州跌超8%， 荣昌生物、百利天恒纷纷下挫。消息面上，特朗普将签署行政令，药价将立即降低30%-80%。 ...

早盘 创新药概念集体回调， 迈威生物跌超10%， 百济神州、 信立泰双双跌超8%， 益方生物、 舒泰 神、 热景生物、 百利天恒、 诺诚健华等跌幅靠前。 ...

Core Viewpoint - The chairman of Maiwei Biotech, Liu Datao, is under investigation by the China Securities Regulatory Commission (CSRC) for suspected short-term trading, which raises concerns about the company's governance and operational stability [2][3]. Financial Performance - Over the past six years, Maiwei Biotech has accumulated a total revenue of 410 million yuan, while suffering a net loss of approximately 5.4 billion yuan [6][7]. - In 2023 and 2024, the company reported consecutive losses exceeding 1 billion yuan, with net losses of 1.053 billion yuan and 1.044 billion yuan respectively [6][7]. - The Q1 2025 report shows a revenue of 44.79 million yuan, a year-on-year decrease of 33.70%, and a net loss of 292 million yuan, a decline of 41.85% [8][10]. Product and Sales Performance - Maiwei Biotech has successfully launched three major products, contributing to a sales revenue of 145 million yuan in 2024, which represents a year-on-year increase of 243.53% [6][7]. - The sales revenue from the drug Deshu Single Antibody reached 139 million yuan in 2024, marking a year-on-year growth of 230.17% [6]. Cost Structure - Sales expenses have surged significantly, with figures of 21.24 million yuan, 78.53 million yuan, and 143 million yuan from 2021 to 2023, reflecting increases of 810.26%, 269.76%, and 81.99% respectively [9]. - In 2024, sales expenses reached 192 million yuan, accounting for 96% of the company's revenue during the same period [9]. Research and Development - Research and development expenses from 2021 to 2023 were 623 million yuan, 759 million yuan, and 836 million yuan, with year-on-year growth rates of 7.08%, 21.86%, and 10.17% respectively [9]. - In 2024, R&D expenses decreased to 783 million yuan, a decline of 6.33% [10]. Debt and Financial Health - As of Q1 2025, the company's debt-to-asset ratio reached 69.86%, the highest since its listing [10]. - The company reported cash and cash equivalents of 1.12 billion yuan, a year-on-year decrease of 34.99%, while short-term and long-term borrowings increased to 1.073 billion yuan and 962 million yuan, reflecting increases of 58.46% and a decrease of 5.87% respectively [10].

Core Viewpoint - The company, Maiwei Biotech, is under investigation by the China Securities Regulatory Commission (CSRC) for suspected short-term trading involving its chairman and general manager, Liu Datao, but this investigation is stated to not significantly impact the company's daily operations [1] Group 1: Company Overview - Maiwei Biotech is an innovative biopharmaceutical company with a full industry chain layout, focusing on products such as antibodies, ADC drugs, recombinant proteins, and small molecule chemical drugs [3] - The company has not yet achieved profitability and has accumulated losses exceeding 3 billion yuan over the past three years [5] Group 2: Financial Performance - From 2022 to 2024, the company's net profits were reported as -955 million yuan, -1.053 billion yuan, and -1.044 billion yuan respectively, indicating consistent losses [5] - In 2024, the company achieved approximately 200 million yuan in revenue, representing a year-on-year growth of 56.28%, while still reporting a net loss of 1.044 billion yuan [5] Group 3: Funding and Market Position - Maiwei Biotech was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board in January 2022, raising a net amount of 3.303 billion yuan [7] - The company is currently advancing its IPO process in Hong Kong, having submitted an application to the Hong Kong Stock Exchange for H-share listing on January 6, 2025 [7] - As of May 9, the company's stock price closed at 19.99 yuan per share, with a total market capitalization of 7.988 billion yuan [7]

Policy Developments - The new draft of the "Further Optimization of Drug Procurement Policy" has circulated in the industry, emphasizing the procurement of medical consumables alongside drugs, enhancing policy flexibility [1] - Since the implementation of the "4+7" volume-based procurement in 2018, the government has organized 10 batches of drug procurement and 5 batches of high-value medical consumables procurement, successfully procuring a total of 435 types of drugs [1] Drug and Device Approvals - Johnson & Johnson's Guselkumab has received approval for a new indication in China for treating moderate to severe active ulcerative colitis in adults who have inadequate response to traditional therapies or biologics [2] - Fosun Pharma's subsidiary has received FDA approval to conduct clinical trials for LBP-ShC4, a live biotherapeutic product aimed at treating androgenetic alopecia, with a cumulative R&D investment of approximately 0.17 million yuan by April 2025 [3] - Reindeer Biologics announced that its CAR-T cell therapy product, Ikigai, has received orphan drug designation from the Saudi FDA for treating relapsed or refractory multiple myeloma in adults [4] Capital Markets - HAYA Therapeutics has completed a $65 million Series A financing round to accelerate the clinical development of its long non-coding RNA-targeted candidate drug HTX-001 for heart failure [5] Regulatory Actions - Pace Double Forest Biopharmaceuticals received administrative regulatory measures from the Shanxi Securities Regulatory Bureau due to internal control deficiencies and inaccurate information disclosure [6] - Maiwei Biotech's chairman received a notice of investigation from the China Securities Regulatory Commission for suspected short-term trading, which is not expected to significantly impact the company's daily operations [7] - Tibet Weixin Pharmaceutical's subsidiary has withdrawn its drug registration application for a pediatric compound amino acid injection, which is not yet marketed in China [8]